Impact of Molnupiravir Treatment on Patient-Reported COVID-19 Symptoms in the Phase 3 MOVe-OUT Trial: A Randomized, Placebo-Controlled Trial
Y Guan, A Puenpatom, MG Johnson… - Clinical Infectious …, 2023 - academic.oup.com
Background Molnupiravir is an orally administered antiviral authorized for COVID-19
treatment in adults at high risk of progression to severe disease. Here, we report secondary …
treatment in adults at high risk of progression to severe disease. Here, we report secondary …
[HTML][HTML] Impact of Molnupiravir Treatment on Patient-Reported COVID-19 Symptoms in the Phase 3 MOVe-OUT Trial: A Randomized, Placebo-Controlled Trial
Y Guan, A Puenpatom, MG Johnson… - … Diseases: An Official …, 2023 - ncbi.nlm.nih.gov
Background Molnupiravir is an orally administered antiviral authorized for COVID-19
treatment in adults at high risk of progression to severe disease. Here, we report secondary …
treatment in adults at high risk of progression to severe disease. Here, we report secondary …
[PDF][PDF] Impact of Molnupiravir Treatment on Patient-Reported COVID-19 Symptoms in the Phase 3 MOVe-OUT Trial: A Randomized, Placebo-Controlled Trial
Y Guan, A Puenpatom, MG Johnson… - Clinical Infectious …, 2023 - pdfs.semanticscholar.org
Background. Molnupiravir is an orally administered antiviral authorized for COVID-19
treatment in adults at high risk of progression to severe disease. Here, we report secondary …
treatment in adults at high risk of progression to severe disease. Here, we report secondary …
[PDF][PDF] Impact of Molnupiravir Treatment on Patient-Reported COVID-19 Symptoms in the Phase 3 MOVe-OUT Trial: A Randomized, Placebo-Controlled Trial
Y Guan, A Puenpatom, MG Johnson… - Clinical Infectious …, 2023 - scienceopen.com
Background. Molnupiravir is an orally administered antiviral authorized for COVID-19
treatment in adults at high risk of progression to severe disease. Here, we report secondary …
treatment in adults at high risk of progression to severe disease. Here, we report secondary …
Impact of Molnupiravir Treatment on Patient-Reported COVID-19 Symptoms in the Phase 3 MOVe-OUT Trial: A Randomized, Placebo-Controlled Trial.
Y Guan, A Puenpatom, MG Johnson… - … Diseases: an Official …, 2023 - europepmc.org
Background Molnupiravir is an orally administered antiviral authorized for COVID-19
treatment in adults at high risk of progression to severe disease. Here, we report secondary …
treatment in adults at high risk of progression to severe disease. Here, we report secondary …
Impact of Molnupiravir Treatment on Patient-Reported COVID-19 Symptoms in the Phase 3 MOVe-OUT Trial: A Randomized, Placebo-Controlled Trial
Y Guan, A Puenpatom, MG Johnson… - … publication of the …, 2023 - pubmed.ncbi.nlm.nih.gov
Background Molnupiravir is an orally administered antiviral authorized for COVID-19
treatment in adults at high risk of progression to severe disease. Here, we report secondary …
treatment in adults at high risk of progression to severe disease. Here, we report secondary …
[HTML][HTML] Impact of Molnupiravir Treatment on Patient-Reported COVID-19 Symptoms in the Phase 3 MOVe-OUT Trial: A Randomized, Placebo-Controlled Trial
Y Guan, A Puenpatom, MG Johnson… - Clinical Infectious …, 2023 - academic.oup.com
Background Molnupiravir is an orally administered antiviral authorized for COVID-19
treatment in adults at high risk of progression to severe disease. Here, we report secondary …
treatment in adults at high risk of progression to severe disease. Here, we report secondary …